<qa>  What is a condition that is not clinically significant?1. Any clinically significant acute or chronic medical condition or need for chronic medications that, in the opinion of the investigator, will interfere with immunity or affect safety Includes, but is not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmuneinflammatory conditions Receipt of systemic, prescription medications for the treatment of chronic medical conditions or variations of normal physiologic functions are permissible if, in the opinion of the investigator, they are used for conditions that are not clinically significant and would not impact the safety of the subject or the safety and immunogenicity outcomes of the protocol. Use of systemic, over-the-counter medications and PRN systemic, prescription medication are allowed if, in the opinion of the investigator, they pose no additional risk to subject safety or assessment of immunogenicityreactogenicity. Topical except corticosteroid medications, nasal including corticosteroid medications, vitamins, and supplements are permissible 2. Asthma, other than mild, well-controlled asthma Cold or exercise induced asthma controlled with inhaled medications other than inhaled corticosteroids is permissible. Participants should be excluded if they require daily bronchodilator use, or have had an asthma exacerbation requiring oralparenteral steroid use or have used theophylline or inhaled corticosteroids in the past year 3. Diabetes mellitus 4. Unstable depression or bipolar disorder Has received 3 months of the same anti-depressant or bipolar disorder medications and dose or has had a decompensating event during the previous 3 months or has depression or bipolar disorder that in the opinion of the investigator will compromise the subjects ability to comply with protocol requirements 5. Unstable seizure disorder defined as requiring medication for seizure control or with seizure activity within the past 3 years 6. Autoimmune disease lupus, multiple sclerosis, rheumatoid arthritis, autoimmune thyroid disease, etc.; vitiligo, and mild eczema or mild psoriasis not requiring chronic therapy are permissible. 7. Known or suspected congenital or acquired immunodeficiency including anatomic or functional asplenia or immunosupppression as a result of underlying illness or treatment 8. Abuse of alcohol or drugs that, in the opinion of the investigator, may interfere with the subjects ability to comply with the protocol 9. Unstable hypertension well-controlled hypertension with medication is permissible 10. Body mass index BMI 35 11. Known allergy to components of the study product .Including the following: aluminum hydroxide, sorbitol, potassium chloride, sodium chloride 12. Seropositive to West Nile virus 13. History of a visit to South America or sub-Saharan Africa lasting one month or more 14. History of military service 15. History of vaccination against yellow fever, tick-borne encephalitis, or Japanese encephalitis 16. History of vaccination with West Nile virus candidate vaccines. 17. Attended primary grade school in Austria, Germany, Japan, South Korea, India, Thailand, Nepal, Vietnam, or Taiwan where tick-borne encephalitis vaccine is given 18. History of dengue fever or receipt of a dengue fever vaccine 19. Active neoplastic disease Participants with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy has been observed for a period that in the investigators estimation provides a reasonable assurance of sustained cure not less than 36 months 20. Chronic topical or systemic corticoste roid use Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons using a topical corticosteroid for a limited duration for mild uncomplicated dermatitis such as poison ivy or contact dermatitis may be enrolled the day after their therapy is completed. Oral or parenteral intravenous, subcutaneous or intramuscular corticosteroids given for non-chronic conditions not expected to recur are permissible if, within the year prior to enrollment, the longest course of therapy was no more than 14 days and no oral or parenteral corticosteroids were given within 30 days prior to enrollment. Intraarticular, bursal, tendon, or epidural injections of corticosteroids are permissible if the most recent injection was at least 30 days prior to enrollment. 21. Are breastfeeding or plan to breastfeed at any time throughout the study 22. Receipt or planned receipt of inactivated vaccine or allergy desensitization injection 14 days before or after a study vaccination 23. Receipt or planned receipt of live attenuated vaccine 30 days before or after a study vaccination 24. Receipt of any other experimental agent within 30 days prior to vaccination or planned receipt prior to the end of the study 25. Plans to enroll in another clinical trial that could interfere with safety assessment of the investigational product at any time during the study period Includes trials that have a study intervention such as a drug, biologic, or device 26 Receipt of blood products or immunoglobulin within six months prior enrollment 27. Donation of a unit of blood within 56 days prior to enrollment or intends to donate blood during the study period 28. Systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg 29.Resting heart rate 40 or 100 beats per minute 30.Oral temperature 38 degrees C 100.4 degrees F 31.Positive serology for HIV 12 If the enzyme linked immunosorbent assay ELISA is positive, HIV confirmation should be performed. If the HIV Western Blot is not consistent with HIV infection, the volunteer may be enrolled. A past participant in an HIV vaccine trial who has a positive antibody ELISA may participate if the Western Blot is not consistent with pending seroconversion or positive or an HIV polymerase chain reaction PCR assay result is below the level of detection of HIV. 32. Positive hepatitis B surface antigen HBsAg 33. Positive antibody to hepatitis C virus HCV 34. Any Grade 1 or higher screening clinical lab value see Toxicity Table Appendix B Screening clinical labs include blood tests white blood cell WBC count, hemoglobin level, platelet count, creatinine, blood urea nitrogen, non-fasting glucose, potassium, alanine aminotransferase ALT, aspartate aminotransferase AST, and total bilirubin and urine tests protein, glucose. 35. Plan to have a major change in exercise routine from 72 hours before any dose of study vaccineplacebo through 15 days after that dose 36. Acute febrile illness oral temperature 38 deg 